The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004

English version České info

Background:
The widespread use of antiretroviral therapies has led to considerable concerns about the prevalence of drug-resistant, as transmission of drug-resistant (TDR) strains poses a challenge for the control of the HIV-1 epidemic.

Methods:
We conducted an epidemiological study enrolling treatment-naïve HIV-1-positive subjects at the Peking Union Medical College Hospital since 1991. Drug resistance was determined by submitting the sequences to the Stanford University Network HIV-1 database.

Results:
Of 521 participants, 478 samples were amplified and sequenced successfully. HIV Transmitted drug resistance prevalence in China was determined to be 6.7 %. We did not find significant differences in the TDR rate by demographic characteristics. No significant time trend in the prevalence of overall TDR was observed (p > 0.05).

Conclusions:
We identified an intermediate prevalence of transmitted drug resistance (TDR), exhibiting a stable time trend. These findings enhance our understanding of HIV-1 drug resistance prevalence and time trend, and provide some guidelines for the comprehensive public health strategy of TDR prevention.

Keywords:
HIV, Prevalence, Treatment-naïve, Transmitted drug resistance, Antiretroviral therapy

Autoři: Hanping Li† ¹; Shuai Chang† ^2,3; Yang Han ⁴; Daomin Zhuang ¹; Lin Li ¹; Yongjian Liu ¹; Siyang Liu ¹; Zuoyi Bao ¹; Wenfu Zhang ²; Hongbin Song ²; Taisheng Li ^4*; Jingyun Li ^1*
Působiště autorů: State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Science, No. 0 East Street Fengtai district, Beijing 100071, China. ¹; Institute of Disease Control and Prevention, Academy of Military Medical Science, Beijing 100071, China. ²; Department of Clinical Laboratory, PLA Army General Hospital, Beijing 100700, China. ³; Department of Infectious Disease, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan Wangfujing Dongcheng district, Beijing 100730, China. ⁴
Vyšlo v časopise: BMC Infectious diseases 2016, 16:605
Kategorie: Research article
prolekare.web.journal.doi_sk: https://doi.org/10.1186/s12879-016-1928-x

© 2016 The Author(s).

Open access
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The electronic version of this article is the complete one and can be found online at: http://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-1928-x

Souhrn

Keywords:
HIV, Prevalence, Treatment-naïve, Transmitted drug resistance, Antiretroviral therapy

Zdroje

1. He N, Detels R. The HIV epidemic in China: history, response, and challenge. Cell Res. 2005;15(11-12):825–32.

2. Zhang FJ, Dou ZH, Yu L, Xu JH, Jiao JH, Wang N, Ma Y, Zhao Y, Zhao HX, Chen RY. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis. 2008; 47(6):825–33.

3. Haase AT. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol. 1999; 17:625–56.

4. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science. 1988;242(4882):1168–71.

5. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science. 1988;242(4882):1171–3.

6. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989;243(4899):1731–4.

7. Vercauteren J, Wensing AMJ, van de Vijver DAMC, Albert J, Balotta C, Hamouda O, Kucherer C, Struck D, Schmit JC, Asjo B, et al. Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe. J Infect Dis. 2009;200(10):1503–8.

8. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, Mahle KC, Heneine W, Johnson JA, Hall HI. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010;24(8):1203–12.

9. Yerly S, von Wyl V, Ledergerber B, Boni J, Schupbach J, Burgisser P, Klimkait T, Rickenbach M, Kaiser L, Gunthard HF, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS. 2007;21(16):2223–9.

10. Ross L, Lim ML, Liao Q, Wine B, Rodriguez AE, Weinberg W, Shaefer M. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin Trials. 2007;8(1):1–8.

11. Truong HHM, Kellogg TA, McFarland W, Louie B, Klausner JD, Philip SS, Grant RM. Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. Plos ONE. 2011;6(10):e25281.

12. Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS. 2009;23(6):717–24.

13. Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev. 2012;14(1):17–27.

14. Grgic I, Lepej SZ, Lunar MM, Poljak M, Vince A, Vrakela IB, Planinic A, Seme K, Begovac J. The prevalence of transmitted drug resistance in newly diagnosed HIV-infected individuals in Croatia: The role of transmission clusters of men who have sex with men carrying the T215S surveillance drug resistance mutation. Aids Res Hum Retrov. 2013;29(2):329–36.

15. Castor D, Low A, Evering T, Karmon S, Davis B, Figueroa A, LaMar M, Garmon D, Mehandru S, Markowitz M. Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. Jaids J Acq Imm Def. 2012;61(1):1–8.

16. Hattori J, Shiino T, Gatanaga H, Yoshida S, Watanabe D, Minami R, Sadamasu K, Kondo M, Mori H, Ueda M, et al. Trends in transmitted drugresistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antiviral Res. 2010;88(1):72–9.

17. Chan PA, Kantor R. Transmitted drug resistance in nonsubtype B HIV-1 infection. HIV Ther. 2009;3(5):447–65.

18. Pineda-Pena AC, Schrooten Y, Vinken L, Ferreira F, Li G, Trovao NS, Khouri R, Derdelinckx I, De Munter P, Kucherer C, et al. Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic. Plos ONE. 2014;9(7):e101738.

19. Frange P, Assoumou L, Descamps D, Cheret A, Goujard C, Tran L, Gousset M, Avettand-Fenoel V, Bocket L, Fafi-Kremer S, et al. HIV-1 subtype Binfected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies. J Antimicrob Chemother. 2015;70(7):2084–9.

20. Li G, Liang S, Harrison TJ, Tang Z, Shen Z, Wang X, Wu X, Liu W, Liang F, Feng L, et al. Prevalence of transmitted HIV-1 drug resistance remains low in Guangxi, China, eight years after scale-up of highly-active antiretroviral therapy. Intervirology. 2014;57(5):270–6.

21. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet. 1999;354(9180):729–33.

22. Liao L, Xing H, Shang H, Li J, Zhong P, Kang L, Cheng H, Si X, Jiang S, Li X, et al. The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr. 2010;53 Suppl 1:S10–14.

23. Liao L, Xing H, Dong Y, Qin G, Ma Y, Lu H, Chen L, Zhang L, Osborne C, Seguy N, et al. Surveys of transmitted HIV drug resistance in 7 geographic Regions in China, 2008-2009. Clin Infect Dis. 2012;54 Suppl 4:S320–323.

24. Stanford University Network HIV-1 database; 2016. http://hivdb.stanford.edu. Accessed 24 Oct 2016.

25. HIV Database. 2016. http://www.hiv.lanl.gov. Accessed 24 Oct 2016.

26. He X, Xing H, Ruan Y, Hong K, Cheng C, Hu Y, Xin R, Wei J, Feng Y, Hsi JH, et al. A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. Plos ONE. 2012;7(10):e47289.

27. Han X, An M, Zhang W, Cai W, Chen X, Takebe Y, Shang H. Genome Sequences of a Novel HIV-1 Circulating Recombinant Form, CRF55_01B, Identified in China. Genome Announc. 2013, 1(1). doi: 10.1128/genomeA. 00050-12.

28. Zhang LQ, Chen ZW, Cao YZ, Yu J, Li GH, Yu WJ, Yin N, Mel S, Li L, Balfe P, et al. Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in China. J Virol. 2004;78(24):13591–9.

29. Chen M, Ma YL, Duan S, Xing H, Yao ST, Su YZ, Luo HB, Yang L, Chen HC, Fu LR, et al. Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China. BMC Infect Dis. 2012;12:382.

30. Zhang Z, Hamatake R, Hong Z. Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Antivir Chem Chemother. 2004;15(3):121–34.

31. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, et al. Prevalence of drugresistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192(6):958–66.

32. Li Y, Gu L, Han Y, Xie J, Wang H, Lv W, Song X, Li Y, Iwamoto A, Ishida T, et al. HIV-1 subtype B/B' and baseline drug resistance mutation are associated with virologic failure: a multicenter cohort study in China. J Acquir Immune Defic Syndr. 2015;68(3):289–97.

33. Brenner BG. Resistance and viral subtypes: how important are the differences and why do they occur? Curr Opin HIV AIDS. 2007;2(2):94–102.

34. Su B, Liu L, Wang F, Gui X, Zhao M, Tien P, Zhang L, Chen Z. HIV-1 subtype B' dictates the AIDS epidemic among paid blood donors in the Henan and Hubei provinces of China. Aids. 2003;17(17):2515–20.

35. Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, Kimmel AD, Freedberg KA. Use of genotypic resistance testing to guide HIV therapy: Clinical impact and cost-effectiveness. Ann Intern Med. 2001;134(6):440–50.

36. Sendi P, Gunthard HF, Simcock M, Ledergerber B, Schupbach J, Battegay M. Cost-effectiveness of genotypic antiretroviral resistance testing in HIVinfected patients with treatment failure. Plos ONE. 2007;2(1):e173.

37. Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, Phillips A, Pillay D, Porter K, Pozniak A, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 2005;331(7529):1368.

38. Little SJ, Holte S, Routy J-P, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, et al. Antiretroviral-Drug Resistance among Patients Recently Infected with HIV. N Engl J Med. 2002;347(6):385–94.